πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Theravance Biopharma Ireland Patents

Full USPTO pharma patent portfolio for Theravance Biopharma Ireland β€” grant dates, expiration, and drug cross-links.

Patents
635
Expiring ≀24m
58

Quick answer

Theravance Biopharma Ireland has 635 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 58 expire within 24 months β€” use filters for patent-cliff planning.

Page 4 of 14

  1. US 9873685

    Neprilysin inhibitors

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9873692

    Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9872855

    (2R,4R)-5-(5β€²-Chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9873696

    Neprilysin inhibitors

    Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9868698

    (2S,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9845332

    Neprilysin inhibitors

    Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9839639

    Neprilysin inhibitors

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9840460

    Neprilysin inhibitors

    Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9828367

    Neprilysin inhibitors

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9783507

    Neprilysin inhibitors

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9771350

    Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activity

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9771337

    Neprilysin inhibitors

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9765028

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9724359

    Neprilysin inhibitors

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9725448

    Neprilysin inhibitors

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9725470

    Substituted naphthyridines as JAK kinase inhibitors

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9688616

    Neprilysin inhibitors

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9688692

    Neprilysin inhibitors

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9683002

    Neprilysin inhibitors

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9682052

    Neprilysin inhibitors

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9682957

    Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activity

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9675599

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9670140

    Neprilysin inhibitors

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9670186

    Neprilysin inhibitors

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9669027

    Hepatitis C virus inhibitors

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9670143

    (2S,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9663509

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9656993

    Crystalline forms of a biphenyl compound

    Expires Mon May 18 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9630960

    Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9593110

    Neprilysin inhibitors

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9585882

    Neprilysin inhibitors

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9572802

    Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activity

    Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9555041

    Neprilysin inhibitors

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9533962

    (2R,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9499487

    Neprilysin inhibitors

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9487514

    Neprilysin inhibitors

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9452161

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9433598

    (2S,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9428457

    Neprilysin inhibitors

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9428489

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9422245

    Neprilysin inhibitors

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9415041

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9402840

    Crystalline form of a quinolinone-carboxamide compound

    Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9394275

    Diamide compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9388145

    Neprilysin inhibitors

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9365549

    Hepatitis C virus inhibitors

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9353106

    Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9334245

    Neprilysin inhibitors

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Theravance Biopharma Ireland have?

635 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Theravance Biopharma Ireland patents expire?

58 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.